Trends and Predictors of Antihypertensive Medication Adherence in Commercially Insured Adults under 65 (2018–2023)
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von N M Mahmudul Alam Bhuiya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Understanding class‐specific antihypertensive adherence is crucial for optimizing hypertension management. This retrospective cohort study analyzed adherence to antihypertensive medication among commercially insured adults (18–64 years) from 2018 to 2023 using Merative MarketScan data. Adherence was defined as the proportion of days covered (PDC) ≥ 80%. Among 2 770 855 hypertensive patients with single‐pill therapy, the majority were older (43% aged 55–64 years) and predominantly male (53%). The South had the highest prevalence of hypertension (53%). Overall adherence improved significantly from 56.61% in 2018–2019 to 75.55% in 2022–2023 across all medication classes. Patients receiving angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) combination therapies had the highest adherence rate (79.18%), while diuretics (67.58%) and “Other Drugs” (57.38%) had the lowest in 2022–2023. Logistic regression showed that younger patients (18–34 years) were significantly less adherent than older adults (OR = 0.434, 95% CI: 0.420–0.448). Males were more likely to adhere than females (OR = 1.142, 95% CI: 1.129–1.156). Regional variations were notable, with patients in the Northeast exhibiting 15% higher adherence than those in the West. Insurance types also influenced adherence, with managed care plan enrollees showing better adherence than those in fee‐for‐service plans (OR = 1.165, 95% CI: 1.151–1.179). Surprisingly, prescription refill monitoring reduced adherence, decreasing odds by 52% (OR = 0.482, 95% CI: 0.470–0.490). Monotherapy and combination therapy users differed significantly across all demographics ( p < 0.0001). Higher comorbidity burden correlated with lower adherence, with diabetes being most prevalent among users of diuretics (12.88%), beta‐blockers (12.8%), and other antihypertensives (26.01%). These findings highlight the multifaceted barriers to antihypertensive adherence and emphasize the need for targeted interventions that address medication‐specific and patient‐specific factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA.
ORCID-Profile: N M Mahmudul Alam Bhuiya
Zitieren
APA
Bhuiya, N. M. M. A., Caballero, J., Young, H. N., & Villa Zapata, L. (2025). Trends and Predictors of Antihypertensive Medication Adherence in Commercially Insured Adults under 65 (2018–2023). The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70108
Vancouver
Bhuiya NMMA, Caballero J, Young HN, Villa Zapata L. Trends and Predictors of Antihypertensive Medication Adherence in Commercially Insured Adults under 65 (2018–2023). The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70108
BibTeX
@article{Bhuiya2025,
author = {Bhuiya, N M Mahmudul Alam and Caballero, Joshua and Young, Henry N and Villa Zapata, Lorenzo},
title = {Trends and Predictors of Antihypertensive Medication Adherence in Commercially Insured Adults under 65 (2018–2023)},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70108}
}
EUVIMED